{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T17:37:55Z","timestamp":1792690675054,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T00:00:00Z","timestamp":1655596800000},"content-version":"am","delay-in-days":353,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.ygyno.2021.04.015","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T18:24:58Z","timestamp":1618597498000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer"],"prefix":"10.1016","volume":"162","author":[{"given":"Vijayalaxmi G.","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Hirst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shariska","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine F.","family":"Roby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Kusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makena L.","family":"Clive","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Jewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh B.","family":"Pathak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew K.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta A.","family":"Crispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Cybulla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Vindigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine C.","family":"Fuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dineo","family":"Khabele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2021.04.015_bb0005","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0010","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ygyno.2020.08.035","article-title":"Homologous recombination deficiency real-time clinical assays, ready or not?","volume":"159","author":"Fuh","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0015","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf9246","article-title":"Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action","volume":"8","author":"Pommier","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0020","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0025","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/annonc\/mdy174","article-title":"Latest clinical evidence and further development of PARP inhibitors in ovarian cancer","volume":"29","author":"Mirza","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0030","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0035","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0040","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0045","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1073\/pnas.92.6.2298","article-title":"Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes","volume":"92","author":"Haaf","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0050","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0092-8674(00)81847-4","article-title":"Association of BRCA1 with Rad51 in mitotic and meiotic cells","volume":"88","author":"Scully","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0055","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1038\/s41467-020-16443-x","article-title":"The bromodomain containing protein BRD-9 orchestrates RAD51-RAD54 complex formation and regulates homologous recombination-mediated repair","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0060","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-20-0818","article-title":"Genetically defined syngeneic mouse models of ovarian cancer as tools for the discovery of combination immunotherapy","volume":"11","author":"Iyer","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0065","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","article-title":"Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2020.01.038","article-title":"CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes","volume":"157","author":"Petersen","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-021-01317-w","article-title":"Reduced SKP1 and CUL1 expression underlies increases in Cyclin E1 and chromosome instability in cellular precursors of high-grade serous ovarian cancer","author":"Lepage","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0080","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/modpathol.2016.101","article-title":"CCNE1 amplification and centrosome number abnormality in serous tubal intraepithelial carcinoma: further evidence supporting its role as a precursor of ovarian high-grade serous carcinoma","volume":"29","author":"Kuhn","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0085","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1158\/0008-5472.CAN-13-2247","article-title":"Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers","volume":"74","author":"Karst","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0090","doi-asserted-by":"crossref","first-page":"19489","DOI":"10.1073\/pnas.1314302110","article-title":"Synthetic lethality between CCNE1 amplification and loss of BRCA1","volume":"110","author":"Etemadmoghadam","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0095","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ygyno.2016.07.088","article-title":"Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib","volume":"143","author":"Wilson","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0100","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.09.016","article-title":"Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer","volume":"127","author":"Wilson","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2014.03.007","article-title":"Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer","volume":"133","author":"Konstantinopoulos","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0110","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.molcel.2008.02.030","article-title":"Deletion of histone deacetylase 3 reveals critical roles in S phase progression and DNA damage control","volume":"30","author":"Bhaskara","year":"2008","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0115","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","article-title":"Hdac3 is essential for the maintenance of chromatin structure and genome stability","volume":"18","author":"Bhaskara","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0120","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1158\/0008-5472.CAN-09-3028","article-title":"Inhibition of histone deacetylase in cancer cells slows down replication forks, activates dormant origins, and induces DNA damage","volume":"70","author":"Conti","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0125","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.canlet.2009.02.042","article-title":"Enhancing the apoptotic and therapeutic effects of HDAC inhibitors","volume":"280","author":"Frew","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0130","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0135","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3389\/fonc.2014.00111","article-title":"The therapeutic potential of class I selective histone deacetylase inhibitors in ovarian cancer","volume":"4","author":"Khabele","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123052","article-title":"Class I-histone deacetylase (HDAC) inhibition is superior to pan-HDAC inhibition in modulating cisplatin potency in high grade serous ovarian cancer cell lines","volume":"20","author":"Bandolik","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0145","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/ncomms3126","article-title":"Evaluating cell lines as tumour models by comparison of genomic profiles","volume":"4","author":"Domcke","year":"2013","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0150","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2310\/7290.2009.00007","article-title":"In vivo pharmacodynamic imaging of proteasome inhibition","volume":"8","author":"Kimbrel","year":"2009","journal-title":"Mol. Imaging"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ygyno.2018.03.049","article-title":"The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer","volume":"149","author":"Wilson","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0160","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0165","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1158\/0008-5472.CAN-17-3993","article-title":"Licofelone enhances the efficacy of paclitaxel in ovarian cancer by reversing drug resistance and tumor stem-like properties","volume":"78","author":"Hirst","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0170","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1385\/MB:26:3:249","article-title":"The comet assay for DNA damage and repair: principles, applications, and limitations","volume":"26","author":"Collins","year":"2004","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0175","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1002\/0471140856.tx0312s65","article-title":"Alkaline comet assay for assessing DNA damage in individual cells","volume":"65","author":"Pu","year":"2015","journal-title":"Curr. Protoc. Toxicol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0180","doi-asserted-by":"crossref","first-page":"4504895","DOI":"10.1155\/2018\/4504895","article-title":"Nanosecond electric pulses induce early and late phases of DNA damage and cell death in cisplatin-resistant human ovarian cancer cells","volume":"2018","author":"Qian","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0185","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.celrep.2017.11.095","article-title":"BET bromodomain inhibition synergizes with PARP inhibitor in epithelial ovarian cancer","volume":"21","author":"Karakashev","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0190","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12943-015-0463-5","article-title":"Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer","volume":"14","author":"Wilson","year":"2015","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0195","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13048-015-0177-8","article-title":"Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer","volume":"8","author":"Wilson","year":"2015","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0200","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nsmb.2501","article-title":"Human RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition","volume":"20","author":"Berti","year":"2013","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0205","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/bs.mie.2017.03.019","article-title":"DNA fiber analysis: mind the gap!","volume":"591","author":"Quinet","year":"2017","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.molcel.2019.10.008","article-title":"PRIMPOL-mediated adaptive response suppresses replication fork reversal in BRCA-deficient cells","volume":"77","author":"Quinet","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0215","doi-asserted-by":"crossref","first-page":"100699","DOI":"10.1016\/j.gore.2021.100699","article-title":"PARPi after PARPi in epithelial ovarian cancer","volume":"35","author":"Essel","year":"2021","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0220","first-page":"1","article-title":"Poly (ADP-ribose) polymerase (PARP) as target for the treatment of epithelial ovarian cancer: what to know","author":"Della Corte","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0225","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acs.jmedchem.6b00990","article-title":"Structural basis for potency and promiscuity in poly(ADP-ribose) polymerase (PARP) and tankyrase inhibitors","volume":"60","author":"Thorsell","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0230","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2018.01.011","article-title":"The poly (ADP ribose) polymerase inhibitor niraparib: management of toxicities","volume":"149","author":"Moore","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0235","doi-asserted-by":"crossref","first-page":"37080","DOI":"10.18632\/oncotarget.26354","article-title":"A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models","volume":"9","author":"Sun","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0240","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s12276-021-00557-3","article-title":"Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance","volume":"53","author":"Kim","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0245","doi-asserted-by":"crossref","first-page":"484","DOI":"10.4161\/cbt.12.6.15956","article-title":"The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells","volume":"12","author":"Wilson","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0250","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0255","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1200\/JCO.18.02050","article-title":"Moving from poly (ADP-ribose) polymerase inhibition to targeting DNA repair and DNA damage response in cancer therapy","volume":"37","author":"Gourley","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0260","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.hoc.2018.07.006","article-title":"Targeting DNA damage response and repair as a therapeutic strategy for ovarian cancer","volume":"32","author":"Konstantinopoulos","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0265","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0270","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0275","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1878-0261.12573","article-title":"Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells","volume":"13","author":"Schoonen","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0280","doi-asserted-by":"crossref","first-page":"9732","DOI":"10.18632\/oncotarget.6947","article-title":"PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response","volume":"7","author":"Wurster","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0285","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","article-title":"PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications","volume":"19","author":"Zhu","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0290","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1128\/MCB.01290-09","article-title":"Human RECQ1 and RECQ4 helicases play distinct roles in DNA replication initiation","volume":"30","author":"Thangavel","year":"2010","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0295","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1093\/nar\/gky519","article-title":"Perturbing cohesin dynamics drives MRE11 nuclease-dependent replication fork slowing","volume":"47","author":"Carvajal-Maldonado","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0300","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4161\/cbt.6.5.4007","article-title":"Drug-induced inactivation or gene silencing of class I histone deacetylases suppresses ovarian cancer cell growth: implications for therapy","volume":"6","author":"Khabele","year":"2007","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0305","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1757-2215-5-12","article-title":"Thailandepsins are new small molecule class I HDAC inhibitors with potent cytotoxic activity in ovarian cancer cells: a preclinical study of epigenetic ovarian cancer therapy","volume":"5","author":"Wilson","year":"2012","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0310","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/0008-5472.CAN-20-1602","article-title":"Replication gaps underlie BRCA-deficiency and therapy response","volume":"81","author":"Panzarino","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0315","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.apsb.2019.08.008","article-title":"Class I histone deacetylase inhibition is synthetic lethal with BRCA1 deficiency in breast cancer cells","volume":"10","author":"Zhang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ygyno.2021.04.015_bb0320","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00432-019-03118-4","article-title":"Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes","volume":"146","author":"Kiweler","year":"2020","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0325","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/ars.2014.5915","article-title":"Class I HDACs affect DNA replication, repair, and chromatin structure: implications for cancer therapy","volume":"23","author":"Stengel","year":"2015","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ygyno.2021.04.015_bb0330","author":"National Institutes of Health (U.S.)"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821003255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825821003255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:54:52Z","timestamp":1758772492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825821003255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0090825821003255"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.04.015","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Entinostat, a selective HDAC1\/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2021.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}